Bionano Genomics announced that optical genome mapping, OGM, was included for the first time in Thompson and Thompson Genetics and Genomics in Medicine, 9th edition, a textbook regularly used for medical students, genetic counseling students, students in laboratory medicine, and more advanced trainees pursuing American Board of Medical Genetics and Genomics, ABMGG, residency and laboratory fellowships in clinical biochemical genetics, laboratory genetics and genomics, and clinical molecular genetics. “Inclusion in this book is a significant milestone for OGM and for people in the various fields of genome analysis who are looking for ways to move the community forward. We were pleased to see the authors note OGM’s ability to detect clinically relevant SVs that other methods, including LRS, miss, while citing OGM’s potential lower cost and greater accuracy, particularly as the SVs detected by OGM in research may ultimately lead to improved diagnosis and detection of genetic disorders,” added Erik Holmlin, PhD, president and chief executive officer of Bionano.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
- Bionano Genomics files to sell 12.2M shares of common stock for holders
- Bionano Genomics offers to sell up to $35M in convertible senior notes due 2025
- Bionano Genomics announces presentation of OGM utility
- Bionano Genomics implements streamlined operational plan